Gufic Biosciences (BOM:509079) Operating Margin %: 15.71% (As of Mar. 2026) — 18% Above Median


BOM:509079 Gufic Biosciences Ltd BOM:509079
73 GF Score
Price ₹360.15
GF Value ₹407.00
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Gufic Biosciences Operating Margin %?

Gufic Biosciences BOM:509079 -2.09% 73 Operating Margin % is 15.71% as of Mar. 2026, which is 18% above its 10-year median of 13.32. GuruFocus rates BOM:509079 with a GF Score™ of 73/100 and a GF Value™ of ₹407.00 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Gufic Biosciences ranks better than 63.77% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Gufic Biosciences's Operating Income for the three months ended in Mar. 2026 was ₹396 Mil. Gufic Biosciences's Revenue for the three months ended in Mar. 2026 was ₹2,518 Mil. Therefore, Gufic Biosciences's Operating Margin % for the quarter that ended in Mar. 2026 was 15.71%.

Warning Sign:

Gufic Biosciences Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -3.5%.

The historical rank and industry rank for Gufic Biosciences's Operating Margin % or its related term are showing as below:

BOM:509079' s Operating Margin % Range Over the Past 10 Years
Min: 8.02   Med: 13.32   Max: 18.11
Current: 12.77


BOM:509079's Operating Margin % is ranked better than
63.77% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs BOM:509079: 12.77

Gufic Biosciences's 5-Year Average Operating Margin % Growth Rate was -3.50% per year.

Gufic Biosciences's Operating Income for the three months ended in Mar. 2026 was ₹396 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,205 Mil.


Gufic Biosciences  (BOM:509079) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Gufic Biosciences Operating Margin % Related Terms


Gufic Biosciences Operating Margin % Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Operating Margin % Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.11 16.97 17.23 13.86 12.77

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.04 11.43 12.69 10.93 15.71

BOM:509079 vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Operating Margin % falls into.


BOM:509079
73GF Score
Gufic Biosciences Ltd BOM:509079
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Gufic Biosciences's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=1205.03 / 9440.066
=12.77 %

Gufic Biosciences's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=395.616 / 2518.197
=15.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 15.71% mean?
Gufic Biosciences (BOM:509079) has a Operating Margin % of 15.71% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Gufic Biosciences and its competitors. This is 18% above median its historical median of 13.32. Over the past decade, Gufic Biosciences' Operating Margin % has ranged from 8.02 to 18.11. According to the industry distribution chart, Gufic Biosciences ranks #346 out of 955 companies in the Drug Manufacturers industry, placing it in the top 36.2%.
Is Gufic Biosciences' Operating Margin % too high?
Gufic Biosciences' current Operating Margin % of 15.71% is 18% above median its 10-year median of 13.32. Over the past 10 years, this metric has ranged from a low of 8.02 to a high of 18.11. The Drug Manufacturers industry median Operating Margin % is 7.45. Gufic Biosciences' value of 15.71% is 110.9% above this industry median. Based on the distribution chart, Gufic Biosciences ranks #346 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gufic Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #346 out of 955 companies for Operating Margin %. This puts Gufic Biosciences in the upper half of its industry. The industry median Operating Margin % is 7.45. Gufic Biosciences' value of 15.71% is 110.9% above this benchmark. Historically, Gufic Biosciences' own Operating Margin % has ranged from 8.02 to 18.11 over the past decade. While the company's 10-year median is 13.32 vs. the industry median of 7.45, Gufic Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current Operating Margin % of 15.71% is 110.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current Operating Margin % is 15.71%, which is 18% above median its own 10-year median of 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹407.00, compared to a current price of ₹360.15 — trading 11.5% below its estimated fair value. The current Operating Margin % is 15.71%, which is 18% above median its 10-year median of 13.32 and 110.9% above the Drug Manufacturers industry median of 7.45. Gufic Biosciences' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Operating Margin % is 15.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹360.15 is trading 11.5% below its estimated GF Value™ of ₹407.00. GuruFocus considers Gufic Biosciences to be Modestly Undervalued.

Key valuation signals for BOM:509079:

  • Operating Margin %: 15.71% (18% above median its 10-year median of 13.32)
  • GF Value™: ₹407.00 vs. price of ₹360.15 (11.5% below fair value)
  • GF Score™: 73/100 with 6 warning signs
  • Industry Position: 110.9% above the Drug Manufacturers median (#346 of 955)

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
73GF Score

Get the complete analysis for BOM:509079

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹360.15
Price
₹407.00
GF Value